This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koopmans, K. P. Articles by de Vries, E. G.E. Search for Related Content PubMed PubMed Citation Articles by Koopmans, K. P. Articles by de Vries, E. G.E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 5-HYDROXYTRYPTOPHAN Medline Plus Health Information Carcinoid Tumors CT Scans Nuclear Scans Pancreatic Cancer Related Articles Related Correspondence Social Bookmarking                            What's this?

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸F-Dihydroxy-Phenyl-Alanine and ¹¹C-5-Hydroxy-Tryptophan Positron Emission Tomography

Klaas P. Koopmans, Oliver C. Neels, Ido P. Kema, Philip H. Elsinga, Wim J. Sluiter, Koen Vanghillewe, Adrienne H. Brouwers, Pieter L. Jager, Elisabeth G.E. de Vries

From the Departments of Nuclear Medicine and Molecular Imaging, Medical Oncology, Pathology and Laboratory Medicine, and Endocrinology, University Medical Center Groningen, University of Groningen; Department of Radiology, Martini Hospital Groningen, the Netherlands

Corresponding author: Elisabeth G.E. de Vries, MD, PhD, Department of Medical Oncology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands, e-mail: e.g.e.de.vries{at}int.umcg.nl

Purpose To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers.

Patients and Methods Carcinoid (n = 24) or pancreatic islet cell tumor (n = 23) patients with at least one lesion on conventional imaging including somatostatin receptor scintigraphy (SRS) and computed tomography (CT) scan underwent ¹¹C-5-hydroxytryptophan (¹¹C-5-HTP) PET and 6-[F-18]fluoro-L-dihydroxy-phenylalanin (¹⁸F-DOPA) PET. PET findings were compared with a composite reference standard derived from all available imaging along with clinical and cytologic/histologic information.

Results In carcinoid tumor patients, per-patient analysis showed sensitivities for ¹¹C-5-HTP PET, ¹⁸F-DOPA PET, SRS, and CT of 100%, 96%, 86%, 96%, respectively, and in islet cell tumors of 100%, 89%, 78%, 87%, respectively. In carcinoid patients, per-lesion analysis revealed sensitivities for ¹¹C-5-HTP PET, ¹¹C-5-HTP PET/CT, ¹⁸F-DOPA PET, ¹⁸F-DOPA PET/CT, SRS, SRS/CT, and CT alone of, respectively, 78%, 89%, 87%, 98%, 49%, 73%, and 63% and in islet cell tumors of 67%, 96%, 41%, 80%, 46%, 77%, and 68%, respectively. In all carcinoid patients ¹⁸F-DOPA PET and ¹¹C-5-HTP PET detected more lesions than SRS (P < .001). ¹¹C-5-HTP PET was superior to ¹⁸F-DOPA PET in islet cell tumors (P < .0001). In all cases, CT improved the sensitivity of the nuclear scans.

Conclusion ¹⁸F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and ¹¹C-5-HTP PET/CT in islet cell tumor patients.

Supported by Grant No. 2003-2936 from the Dutch Cancer Society.

Presented in part at the 54th Annual Meeting of the Society of Nuclear Medicine June 2-6, 2007, Washington, DC.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Premedication With Carbidopa Masks Positive Finding of Insulinoma and β-Cell Hyperplasia in [¹⁸F]-Dihydroxy-Phenyl-Alanine Positron Emission Tomography
  Saila Kauhanen, Marko Seppänen, and Pirjo Nuutila
  JCO 2008 26: 5307-5308 [Full Text]

This article has been cited by other articles:

				H.-B. Fiebrich, A. H. Brouwers, M. N. Kerstens, M. E. J. Pijl, I. P. Kema, J. R. de Jong, P. L. Jager, P. H. Elsinga, R. A. J. O. Dierckx, J. E. van der Wal, et al. 6-[F-18]Fluoro-L-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3922 - 3930. [Abstract] [Full Text] [PDF]

				F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J.-P. Lotz, P. Ruszniewski, P. Rougier, F. Duron, P. Bouchard, J.-D. Grange, et al. Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1295 - 1301. [Abstract] [Full Text] [PDF]

				H.-B. Fiebrich, A. H. Brouwers, L. van Bergeijk, and G. van den Berg Localization of an Adrenocorticotropin-Producing Pheochromocytoma Using 18F-Dihydroxyphenylalanine Positron Emission Tomography J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 748 - 749. [Full Text] [PDF]

				S. Kauhanen, M. Seppanen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Valimaki, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 255 - 265. [Abstract] [Full Text] [PDF]

				S. N. Pinchot, K. Holen, R. S. Sippel, and H. Chen Carcinoid Tumors Oncologist, December 1, 2008; 13(12): 1255 - 1269. [Abstract] [Full Text] [PDF]

				I. P. Kema, K.-P. Koopmans, P. H. Elsinga, A. H. Brouwers, P. L. Jager, and E. G.E. de Vries In Reply: J. Clin. Oncol., November 10, 2008; 26(32): 5308 - 5309. [Full Text] [PDF]

				S. Kauhanen, M. Seppanen, and P. Nuutila Premedication With Carbidopa Masks Positive Finding of Insulinoma and {beta}-Cell Hyperplasia in [18F]-Dihydroxy-Phenyl-Alanine Positron Emission Tomography J. Clin. Oncol., November 10, 2008; 26(32): 5307 - 5308. [Full Text] [PDF]

				H.-B. Fiebrich, A. H. Brouwers, T. P. Links, and E. G.E. de Vries Myocardial Metastases of Carcinoid Visualized by 18F-Dihydroxy-Phenyl-Alanine Positron Emission Tomography Circulation, October 7, 2008; 118(15): 1602 - 1604. [Full Text] [PDF]

				P. Burman, A. Lethagen, K. Ivancev, L. Johansson, and A. Sundin Dual bronchial carcinoids and Cushing's syndrome with a paradoxical response to dexamethasone and a false positive outcome of inferior petrosal sinus sampling Eur. J. Endocrinol., October 1, 2008; 159(4): 483 - 488. [Abstract] [Full Text] [PDF]

				S. Leboulleux, C. Dromain, A. L. Vataire, D. Malka, A. Auperin, J. Lumbroso, P. Duvillard, D. Elias, D. M. Hartl, T. De Baere, et al. Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3021 - 3028. [Abstract] [Full Text] [PDF]

				K. P. Koopmans, P. L. Jager, I. P. Kema, M. N. Kerstens, F. Albers, and R. P.F. Dullaart 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas J. Nucl. Med., August 1, 2008; 49(8): 1232 - 1237. [Abstract] [Full Text] [PDF]